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Atrophy Expansion Rates in Stargardt
Disease Using Ultra-Wideﬁeld Fundus
Autoﬂuorescence
Rachael C. Heath Jeffery, MChD, MPH,1,2 Jennifer A. Thompson, PhD,3 Johnny Lo, PhD,4
Tina M. Lamey, PhD,1,3 Terri L. McLaren, BSc,1,3 Ian L. McAllister, MD,1 David A. Mackey, MD,1
Ian J. Constable, MD,1 John N. De Roach, PhD,1,3 Fred K. Chen, MBBS, PhD1,2,5
Purpose: To investigate atrophy expansion rate (ER) using ultra-wideﬁeld (UWF) fundus autoﬂuorescence
(FAF) in Stargardt disease (STGD1).
Design: Retrospective, longitudinal study.
Participants: Patients with biallelic ABCA4 mutations who were evaluated with UWF FAF and Heidelberg
30  30 and 55  55 FAF imaging.
Methods: Patients with atrophy secondary to STGD1 were classiﬁed into genotype groups: group A, biallelic
severe or null-like variants with early-onset disease; group B, 1 intermediate variant in trans with severe or null-like
variant; and group C, 1 mild variant in trans with severe or null-like variant or late-onset disease. The boundaries of
deﬁnitely decreased autoﬂuorescence (DDAF) were outlined manually and areas (in square millimeters) were
recorded at baseline and follow-up. Bland-Altman analysis was conducted to examine agreement between observers and devices. Linear mixed modeling was used to evaluate predictors of ER in DDAF area and square root
area (SRA).
Main Outcome Measures: Patient and ocular predictors of DDAF area ER and DDAF SRA ER included age
at onset, duration of symptoms, genotype group, baseline visual acuity, and baseline atrophy size.
Results: A total of 138 eyes from 69 patients (33 men [47%]; mean age  standard deviation, 41  20 years;
range, 10e83 years) carrying 61 unique ABCA4 variants were recruited. Ultra-wideﬁeld FAF measurements were
equivalent to Heidelberg 30  30 imaging. Baseline DDAF area was the only signiﬁcant predictor of DDAF area
ER (P < 0.001). Age at baseline and genotype group were predictors for DDAF SRA ER. Deﬁnitely decreased
autoﬂuorescence area ER ranged from 4.65 mm2/year (group A) to 0.62 mm2/year (group C).
Conclusions: Ultra-wideﬁeld FAF is a feasible and reliable method for assessing atrophy ER in STGD1. The
value of ABCA4 mutation severity in predicting atrophy ER warrants further investigation. Ophthalmology
Science 2021;1:100005 ª 2021 by the American Academy of Ophthalmology. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Supplemental material available at www.ophthalmologyscience.org/.

Stargardt disease (STGD1; Online Mendelian Inheritance in
Man identiﬁer, 248200), caused by biallelic mutations in the
ATP-binding cassette transporter subfamily A4 (ABCA4)
gene, is the most common of all inherited retinal diseases.1e4 The formation and expansion of retinal pigment
epithelium atrophy in the macular region is a hallmark of
STGD1 progression.5 Fundus autoﬂuorescence (FAF)
imaging allows reliable quantiﬁcation of the expansion
rate (ER) in retinal pigment epithelium atrophy as deﬁned
by the area of deﬁnitely decreased autoﬂuorescence
(DDAF).6 Consequently, DDAF area has been proposed
as a trial end point in the treatment of STG1.7 To date,
studies have limited their evaluation of DDAF area to the
central 30  30 ﬁeld of view, although expansion
beyond this region frequently occurs in STGD1.8,9
Notwithstanding
the
emergence
of
ABCA4
ª 2021 by the American Academy of Ophthalmology
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mutation-speciﬁc therapies, a paucity of data is available
on genotype-speciﬁc ER in DDAF area.10e12
Single-center case series and multicenter studies have
used the 30  30 lens on the Heidelberg scanning laser
ophthalmoscope device to capture and measure DDAF
area.7,10e13 Some research groups have enabled the use of
the wideﬁeld 55  55 lens, on the assumption that the
DDAF area is equivalent to the 30  30 view.7,13,14
However, this assumption has not been examined. Most
studies reported the baseline DDAF area as the most
signiﬁcant factor in predicting ER, although the actual
mean baseline DDAF area was relatively small
(0.74e3.93 mm2).7,10,11,13 To eliminate the dependence of
ER on the baseline DDAF area, 2 studies examined the
square root area (SRA) ER.12,14 Lindner et al14 reported
an ER of 0.23 mm/year in SRA by using both 30  30
https://doi.org/10.1016/j.xops.2021.100005
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and 55  55 lenses, whereas Muller et al12 found an ER of
0.20 mm/year in a study using only the 30  30 lens. Both
of these studies reported small baseline lesion sizes of 6.2
mm2 and 1.58 mm2, respectively.12,14 More recently,
Chen et al8 used the ultra-wideﬁeld (UWF) Optos device
to examine lesion extent in STGD1. They found only 26%
of patients with STGD1 harbored lesions conﬁned to the
30  30 ﬁeld. Hence, an unmet clinical need exists to
examine the ER of DDAF that extends beyond the posterior
pole and the dependence of ER on baseline lesion sizes that
are much larger. Several studies have investigated the relationship between genotype and DDAF area ER.10e12
However, their classiﬁcation system was limited to pathogenicity and single variants, rather than the combined
severity of biallelic ABCA4 variants. This study aimed to
evaluate the agreement in DDAF area and SRA between the
Heidelberg 30  30 and 55  55 FAF images and the
Optos UWF FAF images and investigate the impact of
various genotypes classiﬁed by variant severity on ER of
DDAF area and SRA in a large, genetically deﬁned STGD1
cohort.

Methods
Study Design and Population
This was a longitudinal analysis of data that were collected retrospectively and prospectively at the Lions Eye Institute, Perth,
Australia, from June 2011 through December 2020. The study
protocol adhered to the tenets of the Declaration of Helsinki, and
ethics approval was obtained from the Human Ethics Ofﬁce of
Research Enterprise, the University of Western Australia (identiﬁer, RA/4/1/7916), and Sir Charles Gairdner Hospital Human
Research Ethics Committee (identiﬁer, 2001-053). Informed consent was obtained from all study participants.
All patients with both a clinical and genetic molecular diagnosis
of STGD1 who had undergone UWF FAF imaging were eligible
for inclusion. The clinical diagnosis was established by the senior
author (F.K.C.) based on the presence of central vision loss
resulting from macular atrophy with or without surrounding ﬂecks
on fundus examination. Patient DNA was collected through the
Australian Inherited Retinal Disease Registry and DNA Bank,15
and genetic molecular diagnosis was conﬁrmed by Casey Eye
Institute or Molecular Vision Laboratory through the detection of
biphasic, suspected disease-causing variants in ABCA4. Patients
with variants shown to be in trans conﬁguration were included, and
those with only 1 variant in the ABCA4 gene or with 2 or more
variants without evidence of biphasic status were excluded.
Patients were enrolled into 1 of the 3 genotype groups according to the combined severities of the 2 ABCA4 alleles. Group
A showed biallelic null or severe variants or extensive panretinal
degeneration with onset of symptoms before 14 years of age.
Group B showed a known intermediate variant in trans with a null
or severe variant, that is, in a hemizygous-like state. Group C
showed a known mild or hypomorphic variant in a hemizygouslike state or demonstrated clinical features of localized foveal
lesion or foveal-sparing macular lesion with late-onset disease.
Variants were considered null-like if they were a stop mutation or a
frame-shift mutation resulting in a premature stop codon predicted
to undergo nonsense-mediated decay. Missense and splice-site
mutations were assigned null-like or severe status based on published clinical data or in vitro assays.16e18 Patients were recruited
consecutively as they were referred to our center for assessment of

2

suspected STGD1. Clinical data including age, gender, symptom
onset, and best-corrected visual acuity as measured on the Early
Treatment Diabetic Retinopathy Study (ETDRS) chart were
recorded.

Procedures and Outcomes
Ultra-wideﬁeld FAF images were obtained using the Optomap or
the California device (Optos PLC), which captures retinal features
spanning 200 of the internal eye angle from the center of the globe
(approximately 135 ﬁeld angle, covering 892 mm2) using a green
excitation laser at 532 nm.19 The total area of the retina has been
estimated to be 1081.57 mm2 based on the calculation by
Atkinson and Mazo.19 Hence, the maximum retinal area imaged
by the Optos device was approximately 82.5% of the total retina.
Short-wave (excitation l, 488 nm; barrier ﬁlter transmitting l,
500e680 nm) fundus autoﬂuorescence (HRA2; Heidelberg Engineering) with 30  30 and 55  55 lenses also were acquired
with special care to ensure that all atrophic lesions were captured if
possible. All images were graded by 2 expert image graders
(R.C.H.J. and F.K.C.) using the OptosAdvance and Heidelberg
Explorer software. The outermost boundary of DDAF was outlined
manually and the area in planimetric square millimeters was
recorded (Fig 1). Areas of DDAF that extended outside the
posterior pole were included only if they were contiguous with
or within 3 disc diameters of the main central DDAF lesion.
Areas of reduced autoﬂuorescence resulting from masking by
pigment plaques were not included in the DDAF marking.
Subsequently, small DDAF lesions discontinuous from the
primary lesion and pigment plaque masking of autoﬂuorescence
in the extreme periphery were excluded.

Genetic Analysis
Genomic DNA was analyzed using various disease-speciﬁc nextgeneration sequencing SmartPanels, which evolved throughout the
study (Table S1, available at www.ophthalmologyscience.org).20
Identiﬁed candidate ABCA4 mutations were conﬁrmed by Sanger
sequencing (genetic testing performed by Casey Eye Institute
Molecular Diagnostics Laboratory, Portland, OR). Phase
segregation was performed for all families. Variant nomenclature
was described in relationship to ABCA4 coding DNA reference
sequence NM_000350.2 and was reported in accordance with the
recommendations of the Human Genome Variation Society.21
Pathogenicity was assessed as described previously22 and was
interpreted according to the joint guidelines of the American
College of Medical Genetics and Genomics and the Association
for Molecular Pathology23 and associated literature.24

Statistical Analysis
Visual acuity of counting ﬁngers, hand movements, and light
perception were assigned e15, e30, and e45 letter scores,
respectively, based on the mean relative logarithm of minimum angle of resolution values (2.0, 2.3, and 2.6, respectively) assigned to these off-chart measurements using the
Freiburgh test.25,26 Categorical variables were summarized by
frequencies and proportions. Continuous variables were
described by mean  standard deviation (SD). Baseline
features were compared across genotype groups using a 1way analysis of variance test.
Bland-Altman analysis was performed to compare the DDAF
area and SRA measurements by the 2 graders (F.K.C. and
R.C.H.J.). Mean and 95% limits of agreement were calculated.
The DDAF area and SRA derived from the UWF FAF image
(Optos200) and the 30  30 and 55  55 Heidelberg systems
were compared using the Bland-Altman analysis. Only pairs of
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Figure 1. Images showing the outermost boundary of deﬁnitely decreased autoﬂuorescence outlined manually and the area in planimetric square millimeters
(mm2) recorded for (A1, B1, C1, D1) Heidelberg 30  30 fundus autoﬂuorescence (FAF), (A2, B2, C2, D2) Heidelberg 55  55 FAF, and (A3, B3,
C3, D3) ultra-wideﬁeld FAF imaging. Patient shown in C (ID:22) had lesions that spread outside the 30  30 ﬁeld of view. Patient shown in (D) (patient
12) demonstrated widespread lesions that were outside the 30  30 and 55  55 ﬁeld of view.
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FAF images in which all of the atrophic lesions were captured by
both imaging methods were used for Bland-Altman analysis to
prevent bias generated by truncation of an atrophic lesion related
to the small ﬁeld of view. The SRA was determined to eliminate
the dependence of ER on the baseline DDAF area. Interocular
symmetry in DDAF area and SRA were assessed using the
Bland-Altman analysis. Paired sample Student t tests were performed to compare the means to determine the signiﬁcance of
bias.
The ER of DDAF area was calculated using the formula:


 DDAF area finalDDAF area baseline
DDAF area ER mm2 year ¼
:
Followup durationðyearsÞ
Square root transformation of DDAF area was performed before
calculation of ER SRA to adjust for baseline area using the
formula:

DDAF SRA ER ðmm = yearÞ ¼

pﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ pﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
DDAF area final  DDAF area baseline
:
Follow  up durationðyearsÞ

Linear mixed modeling was used to assess patient and ocular
predictors of DDAF area ER and DDAF SRA ER. Right and left
eye measurements were treated as repeated measures. Patient factors recorded included gender, age at symptom onset (years), age at
baseline DDAF assessment (years), and genotype group (A, B, or
C). Ocular measurements included visual acuity (ETDRS letters),
DDAF area (square millimeters), and DDAF SRA (millimeters)
recorded at baseline. Preliminary analyses were conducted to
identify and remove outliers to ensure no violation of the assumptions of normality. Linearity, multicollinearity, and homoscedasticity were examined. Data were analyzed using IBM SPSS
Statistics for Windows software version 26 (IBM Corp). P values
for post hoc testing were adjusted for false discovery rate (FDR).
Statistical tests were considered signiﬁcant at P < 0.05.

Results
Baseline Demographics
A total of 69 patients (33 men [47%]; mean  SD age, 41
 20 years; range, 10e83 years) carrying 61 unique
ABCA4 variants were recruited from 52 families (Table
S2, available at www.ophthalmologyscience.org). The
pathogenicity assessment and severity for each ABCA4
variant are shown in Table S3 (available at
www.ophthalmologyscience.org). Overall, the mean 
SD age at symptom onset and duration of disease were
24.5  22.6 years and 16.3  14.0 years (including 6
patients who were asymptomatic at baseline),
respectively. The mean  SD best-corrected visual acuities were 38  29 ETDRS letters (Snellen equivalent, 20/
174) and 37  31 ETDRS letters (Snellen equivalent, 20/
182) in the right and left eyes, respectively. A signiﬁcant
difference was found in baseline features across the 3
genotype groups for all variables, including age at onset,
age at baseline examination, duration of disease, and
baseline visual acuity (Table 1).
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Eight of the 69 patients (12%) showed no DDAF in
either eye over a mean  SD follow-up of 1.9  1.8 years.
Of the remaining 61 patients with DDAF at baseline, 2 eyes
from 2 patients had ungradable images because of extension
of the DDAF beyond the ﬁeld of view on UWF FAF,
leaving 120 eyes from 61 patients (59 with bilateral disease
and 2 with unilateral disease) with gradable images for
measuring baseline DDAF areas. Of these, 19 eyes of 10
patients did not have follow-up data, leaving 101 eyes of 51
patients (50 with bilateral disease and 1 with unilateral
disease) with paired baseline and follow-up DDAF areas for
calculating ER (Fig 2). The mean  SD DDAF area and
SRA at baseline (n ¼ 59 pairs of eyes) were 23  57
mm2 and 3.3  3.5 mm in the right eye and 25
 69 mm2 and 3.5  3.7 mm in the left eye, respectively.

Interobserver, Interdevice, and Interocular
Agreements
A total of 221 baseline and follow-up Optos UWF FAF
images were marked by the 2 graders. No signiﬁcant difference was found in baseline DDAF area and DDAF SRA
between the 2 image graders (Table 2; Figure S1 (available
at www.ophthalmologyscience.org). Given the agreement
between graders, the averaged DDAF areas were used for
comparison with Heidelberg DDAF and for calculation of
ER in all subsequent analyses.
For interdevice agreement validation, the graders marked
the DDAF boundaries of 51 55  55 and 45 30  30
FAF images from the right eyes of patients with DDAF
visualized entirely within the respective ﬁelds of view. The
interdevice difference in DDAF area between UWF FAF
and Heidelberg 30  30 FAF images increased with larger
lesions (Table 2; Fig 3). However, this relationship was not
evident after square root transformation. Heidelberg 55 
55 FAF imaging tended to overestimate DDAF area
when compared with UWF FAF and Heidelberg 30 
30 imaging systems, respectively (Table 2).
The 2 eyes had similar DDAF area and SRA, but the
limits of agreement were wider than interobserver or interdevice comparisons (Table 2; Fig S2, available at
www.ophthalmologyscience.org).
Predictors of Deﬁnitely Decreased
Autoﬂuorescence Expansion Rates
Preliminary analysis identiﬁed the patient with a DDAF area
ER of 32.29 mm2/year as an outlier, and the individual subsequently was removed from the analysis. Data for 2 other
patients also were removed because the baseline DDAF areas
were more than 390 mm2, whereas all other patients included
in the linear mixed modeling showed DDAF areas of less
than 220 mm2. Deﬁnitely decreased autoﬂuorescence area
was the only signiﬁcant predictor of DDAF area ER (F ¼
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Table 1. Baseline Demographics for Each Genotype Group

Age at symptom onset (yrs)
Age at baseline assessment (yrs)
Disease duration (yrs)
Baseline VA right eye (ETDRS letters)
Baseline DDAF area in right eye (mm2)
Baseline DDAF square-root-area in right eye (mm)
Patients with follow-up data

Group A (n [ 24)

Group B (n [ 21)

Group C (n [ 24)

P Value*

8.9  1.9
28.5  16.1
19.6  16.0
18  23
73 152
5.6  6.6
16 (67)

20.3  14.5
40.6  13.8
20.5  13.9
37  28
18  25
3.5  2.6
20 (95)

44.8  25.6
53.2  20.7
9.2  8.9
59  20
2.9  5.1
1.2  1.2
15 (63)

< 0.001
< 0.001
0.008
< 0.001
0.024
0.003
N/A

DDAF ¼ deﬁnitely decreased autoﬂuorescence; ETDRS ¼ Early Treatment Diabetic Retinopathy Study; N/A ¼ not applicable; VA ¼ visual acuity.
Data are presented as meanstandard deviation or no. (%).
*One-way analysis of variance.

20.516; P < 0.001; Table 3). In contrast, increasing patient
baseline age (F ¼ 7.477; P ¼ 0.008) was associated with
greater DDAF SRA ER, whereas increasing baseline
DDAF SRA was associated with reduced DDAF SRA ER
(F ¼ 5.640; P ¼ 0.020). Furthermore, signiﬁcant
differences in DDAF SRA ER were observed among the
genotypes (F ¼ 3.298; P ¼ 0.046) whereby the mean ER
for genotype C was signiﬁcantly lower than both genotype
group A (P ¼ 0.041, FDR) and group B (P ¼ 0.041,
FDR). No signiﬁcant difference was found in DDAF SRA
ER between genotype groups A and B (P ¼ 0.547, FDR;
Table 3).
The mean ER in DDAF area ranged from 0.62 mm2/year
in the mildest genotype group (group C) to 4.65 mm2/year in
the most severe genotype group (group A). Similarly, the ER
in DDAF SRA ranged from 0.18 mm/year in group C to 0.25
mm/year in group A (Table 4). Figure S3 (available at
www.ophthalmologyscience.org) illustrates the UWF
DDAF baseline and follow-up calculations for each genotype group. A striking contrast exists between the trajectories
of DDAF area or SRA increase for each patient among the 3
genotype groups, as illustrated by Figure 4.

Discussion
This study raises signiﬁcant questions regarding the validity
of using Heidelberg 30  30 and 55  55 viewing
systems interchangeably in DDAF area as reported in previous studies.7,13,14 Furthermore, we demonstrated the
feasibility and usefulness of UWF FAF for measuring
DDAF area expansion across a wide spectrum of STGD1.
In addition to the established predictive factor of DDAF
area ER, our ﬁnding of the association between genotype
group and DDAF SRA ER has signiﬁcant implications for
patient selection and clinical trial designs.
To our knowledge, the feasibility and repeatability of
UWF FAF in the longitudinal assessment of DDAF has not
been reported previously. In our study, we selected UWF
FAF as the primary imaging method to estimate atrophy
enlargement rate in STGD1. To date, short-wavelength
(SW) FAF-based DDAF area measurement using the central 30  30 or 55  55 ﬁeld has been the main outcome
measure in published studies, including the ProgStar
study,9,13 whereas Optos-derived UWF FAF imaging has
not been explored as an end point in this large multicenter

Figure 2. Flow chart showing those patients who were excluded, leaving 101 eyes of 51 patients (50 with bilateral disease and 1 with unilateral disease) with
paired baseline and follow-up deﬁnitely decreased autoﬂuorescence (DDAF) areas. FAF ¼ fundus autoﬂuorescence; STGD1 ¼ Stargardt disease; UWF ¼
ultra-wideﬁeld.
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Table 2. Interobserver, Interdevice, and Interocular Agreements in Deﬁnitely Decreased Autoﬂuorescence Area and Square Root Area
Comparisons

Limits of Agreement*

P Valuey

Sample Size

Mean Difference

61
59

e0.12
e0.46

e3.13 to þ2.87
e4.68 to þ3.73

45
51
44

e0.19
þ2.79
þ1.20

e2.38 to þ1.99
e6.84 to þ12.37
e2.26 to þ4.65

59
50

e2.24
e2.03

e30.41 to þ25.79
e22.75 to þ18.58

0.236
0.180

61
59

e0.02
e0.02

e0.20 to þ0.17
e0.31 to þ0.26

0.168
0.197

45
51
44

e0.03
þ0.27
þ0.16

e0.37 to þ0.30
e0.41 to þ0.91
e0.17 to þ0.49

0.221
< 0.001
< 0.001

59
50

e0.11
e0.13

e1.82 to þ1.60
e2.03 to þ1.75

0.355
0.330

2

DDAF area (mm )
Interobserver
F.K.C. vs. R.C.H.J.z baseline
F.K.C. vs. R.C.H.J.z baseline
Interdevice
O200 vs. H30 RE only
H55 vs. O200 RE only
H55 vs. H30 RE only
Interocular
RE vs. LE baseline
RE vs. LE ﬁnal
DDAF SRA (mm)
Interobserver
F.K.C. vs. R.C.H.J.z baseline
F.K.C. vs. R.C.H.J.z baseline
Interdevice
O200 vs. H30 RE only
H55 vs. O200 RE only
H55 vs. H30 RE only
Interocular
RE vs. LE baseline
RE vs. LE ﬁnal

RE
LE

RE
LE

0.528
0.104
0.266
< 0.001
< 0.001

DDAF ¼ deﬁnitely decreased autoﬂuorescence; LE ¼ left eye; H30 ¼ Heidelberg 30  30 lens; H55 ¼ Heidelberg 55  55 lens; O200 ¼ Optos200
device; RE ¼ right eye; SRA ¼ square root area.
*Bland-Altman 95% limits of agreement deﬁned by mean  1.95  standard deviation.
y
Paired sample t test.
z
Author initials.

trial. The use of UWF FAF has advantages, most notably for
pediatric populations or patients with impaired mobility as
well as for those with disease extending outside of the
central 30  30 or 55  55 ﬁeld. In addition, Chen et al8
found that UWF FAF images can have reduced uniformity,
as compared with SW AF, most pronounced in the superior
and inferior fundus. The reduced visibility was compensated
partially by imaging through a dilated pupil, but the entire
DDAF atrophic lesion was still not visible with UWF
FAF in 2 of 24 patients in group A. Fernanda Ablem
et al27 showed that UWF FAF imaging in STGD1 was
correlated with electroretinography and kinetic perimetry,
thus supporting the use of this more accessible clinical
tool for evaluating both central and peripheral retinal
involvement. Given the ease of use (single ﬂash compared
with prolonged averaging), reduced potential for toxicity,
wider availability, and greater ﬁeld of view of UWF FAF,
we propose that UWF FAF may be more appropriate for
evaluation of larger lesions and should be included in the
assessment of all patients with STGD1. In further support
of UWF FAF, Chen et al8 also reported that fovealsparing lesions were more readily demonstrable by greenwavelength FAF imaging. Müller et al6 also found that
green FAF-based quantiﬁcation of lesion size provided
similar results to SW FAF. Although we provided evidence,
for the ﬁrst time, that the Heidelberg 30  30 imaging
systems is equivalent to Optos UWF FAF imaging with
respect to DDAF area, we also found that Heidelberg 55 
55 FAF imaging tended to overestimate DDAF area when
compared with 30  30 imaging and UWF FAF imaging.

6

Chen et al8 compared the different imaging methods nearinfrared autoﬂuorescence, SW AF, and green UWF FAF
in 34 patients with STGD1 and found that 18 of 34 patients
(53%) harbored lesions extending outside the 55  55
ﬁeld. Similarly, Klufus et al9 found that most patients with
STGD1 demonstrate changes in the peripheral retina.
While comparing the 3 viewing systems, we also found
26% and 16% of patients showed DDAF boundaries
beyond the 30  30 and 55  55 ﬁelds, respectively.
Similar to Müller et al,6 who reported high interobserver
agreement with the 30  30 imaging system, we also
observed good interobserver agreement in DDAF
boundary demarcation for area and SRA measurements
using Optos UWF FAF imaging.
After demonstrating the feasibility of UWF FAF for
measuring DDAF area, we calculated the annual ER of
DDAF area and SRA in STGD1 to investigate predictive
factors. This DDAF area ER was signiﬁcantly greater than
that of previous reports because we did not exclude atrophic
lesions that extended beyond the limits of the 30  30 or
55  55 viewing systems. The mean annual DDAF area
ER was 2.4 mm2/year (range, 0.06e32.3 mm2/year) as
compared with less than 1 mm2/year reported by all
previous studies that also reported varied annual ER
because of differences in baseline atrophy sizes.6e8,12,13
Consistent with previous literature, we also found that
baseline DDAF area was a signiﬁcant predictor of DDAF
area ER.6,12,13 Interestingly, baseline age was associated
positively with DDAF SRA ER, whereas baseline DDAF
SRA was associated negatively with DDAF SRA ER. In a
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Figure 3. Bland-Altman plots demonstrating interdevice and intermethod agreement between the Optos200 and Heidelberg systems and between 30 
30 and 55  55 imaging methods on the Heidelberg system (Optos200 vs. Heidelberg 30  30 , Heidelberg 55  55 vs. Heidelberg 30  30 , and
Heidelberg 55  55 vs. Optos200) for (A1, B1, C1) deﬁnitely decreased autoﬂuorescence (DDAF) area as well as (A2, B2, C2) DDAF square root area
(SRA). The solid line indicates the mean difference and the dashed lines indicate the 95% limits of agreement. Overall, Optos200 and Heidelberg 30  30
DDAF SRA showed similar results.

retrospective study, Strauss et al7 reported a mean annual
DDAF progression rate of 0.51 mm2 (95% conﬁdence
interval, 0.42e0.61 mm2) with a mean  SD baseline
lesion size of 2.2  2.7 mm2 where the rate of

progression depended on the baseline lesion size. In their
subsequent prospective study, the annual DDAF
progression increased to 0.76 mm2 (95% conﬁdence
interval, 0.54e0.97 mm2) as the baseline lesion size also
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Table 3. Linear Mixed Modeling for Predictors of Expansion Rates in Deﬁnitely Decreased Autoﬂuorescence Area and Square Root Area
Deﬁnitely Decreased Autoﬂuorescence Area Expansion
Rate (mm2/yr)
Predictor
Gender
Eye
Genotype
group
Age at
baseline
assessment
(yrs)
Age at
symptom
onset (yrs)
Baseline visual
acuity
Baseline
DDAF area/
SRAx

Category
Female
Male
Left
Right
A
B
C

Data*

Model Estimate  SE

F(v1, v2)y

P Value

Deﬁnitely Decreased Autoﬂuorescence Square
Root Area Expansion Rate (mm/yr)
Model Estimate 
SE

F(v1, v2)y

P Value

F(1, 43.1) ¼ 1.225

0.274

F(1, 47.6) ¼ 0.006

0.939

F(2, 46.2) ¼ 3.298

0.046

F(1, 67.8) ¼ 7.477

0.008

24 (49)
25 (51)
49 (50)
49 (50)
14 (28.6)
20 (40.8)
15 (30.6)
41.3  20.2

e0.188  0.341
1.00 (reference)z
0.046  0.205
1.00 (reference)z
0.25  0.67
0.757  0.502
1.00 (reference)z
0.004  0.023

F(1, 41.5) ¼ 0.304

0.584

F(1, 47.6) ¼ 0.050

0.824

F(2, 42.7) ¼ 1.549

0.224

F(1, 47.4) ¼ 0.025

0.876

e0.042  0.038
1.00 (reference)z
0.001  0.016
1.00 (reference)z
0.169  0.074
0.137  0.056
1.00 (reference)z
0.007  0.003

26  23.2

0.008  0.021

F(1, 49.6) ¼ 0.129

0.721

e0.004  0.002

F(1, 63.6) ¼ 2.466

0.121

39.9  29.9 e0.012  0.009

F(1, 77) ¼ 1.807

0.183

e0.0005  0.001 F(1, 88.3) ¼ 0.293

0.590

16.4  28.3 0.044  0.01

F(1, 52.4) ¼ 20.516

e0.026  0.011

0.020

< 0.001

F(1, 87.1) ¼ 5.640

DDAF ¼ deﬁnitely decreased autoﬂuorescence; SE ¼ standard error; SRA ¼ square root area.
*Presented as no. (%) or mean  standard deviation for continuous variables.
y
Observed F statistic with v1 and v2 degrees of freedom.
z
The reference level in the categorical predictor is deﬁned as 1.00 (reference).
x
Deﬁnitely decreased autoﬂuorescence area was used as the predictor for area expansion rate, whereas DDAF SRA was the predictor for SRA expansion rate.

increased to 3.9  4.4 mm2.13 Within the lesion size
category, Strauss et al7,13 found that the growth rates were
age dependent where a linear mixed model stratiﬁed by
initial lesion size provided the best ﬁt in estimating annual
progression rates. Müller et al6 also reported a low mean
annual DDAF progression rate of 0.89  0.13 mm2. They
found that the number of DDAF lesions, full-ﬁeld electroretinographic ﬁndings, and age at onset were the most signiﬁcant predictors for future growth. Fujinami et al2
reported DDAF progression in 67 patients with STGD1,
of whom only 35 patients underwent mutation screening.
They reported a median annual DDAF progression rate of
only 0.45 mm2 and found the age and size of atrophy at
baseline to be signiﬁcant predictors. Cicinelli et al11 also
found multifocal disease, larger baseline lesion, and worse
visual acuity to be associated with a faster rate of
progression. Lindner et al14 reported an annual DDAF
SRA progression rate of 0.23 mm, which is identical to
our mean ER of 0.23  0.18 mm/year. However, their
study only included 66 eyes from 38 patients 45 years of

age or older, in whom the mean  SD age was 63.4 
9.9 years, in contrast to 24.5  22.6 years in our cohort
and in the Strauss et al13 and Muller et al12 series, where
the mean age was 21.9  13.3 years and 33.6  17.2
years, respectively. Although baseline atrophy size has
been identiﬁed as the key predictor of ER, less is known
about the effect of genotype, especially classiﬁed by the
combined severity of biallelic ABCA4 mutations. Given
the importance of genotype in predicting age at onset and
extent of lesion area, we added genotype group to the
linear mixed model for ER.
A key novel ﬁnding in this study is the effect of genotype
on DDAF SRA ER, whereby the mean ER for genotype
group C was signiﬁcantly lower than that of both genotype
groups A and B. Fujinami et al2 assessed the effect of speciﬁc
STGD1 genotypes on DDAF progression rates and found an
annual median rate of atrophy expansion of 0.45 mm2 and
0.39 mm2 in patients harboring c.5461e10T/C and
c.6079C/T variants, respectively. In contrast, those with
the c.5882G/A variant showed an expansion rate of only

Table 4. Expansion Rate in Deﬁnitely Decreased Autoﬂuorescence Area and Square Root Area for Each Genotype Group

2

Annual DDAF area expansion rate (mm )*
Annual DDAF SRA expansion rate (mm)*

Group A (n [ 16)

Group B (n [ 20)

Group C (n [ 15)

4.65  8.43 (0.06e32.3)
0.25  0.27 (0.01e1.01)

2.00  1.41 (0.14e4.58)
0.25  0.12 (0.06e0.57)

0.62  0.52 (0.00e1.90)
0.18  0.14 (0.00e0.47)

DDAF ¼ deﬁnitely decreased autoﬂuorescence; SRA ¼ square root area.
Data are presented as mean  standard deviation (range).
*Right eye only.
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Figure 4. Graphs showing (A1, B1) deﬁnitely decreased autoﬂuorescence (DDAF) area or (A2, B2) square root area (SRA) expansion for each patient
according to the 3 genotype groups. Group A (red) showed biallelic severe or null-like variants with early-onset disease, group B (blue) showed an intermediate variant in trans with a severe or null-like variant, and group C (orange) carried a mild variant in trans with a severe null-like variant or late-onset
disease.

0.20 mm2/year, suggesting a potential association between
patients carrying 1 truncating or severe variant and more
progressive FAF patterns. Di Iorio et al28 also found a
signiﬁcant association between severe STGD1 phenotypes
and faster progression on OCT. However, both these
studies considered only 1 allele, although the phenotype in
STGD1 is dependent on the combined effect of both
paternal and maternal variants. In contrast, our study takes
into consideration both alleles, with known severities, to
determine the effect of genotype on DDAF progression
rates. In a retrospective cohort study of 28 patients with
STGD1, Cicinelli et al11 found that genetic variants were

not associated with the rate of DDAF progression.
However, their patients were divided into 2 simplistic
genotype groups of (1) patients with 1 or more null
variant or (2) patients with 2 or more missense
variants, which does not take into account the severity
of the impact of these variants on ABCA4 function.
Our results have implications on clinical trials design
regarding inclusion criteria and stratiﬁcation based on
baseline DDAF area as well as genotype characteristics
of the study cohort.
One limitation of our study is the small sample size in the
nullizygous and the hemizygous-like genotype groups. The
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images also were evaluated by 2 unmasked investigators
(R.C.H.J. and F.K.C.) to ensure that all atrophic lesions
were marked. Signiﬁcantly lower numbers of follow-up data
were available for some patients, which limited our investigation of the actual lesion area growth rate for speciﬁc
mutations. Although UWF FAF imaging exhibits less
shadowing with greater penetration of 532-nm light through
the macular pigment, direct correlation in lesion size between Heidelberg Spectralis SW AF 30  30 or 55  55
ﬁelds and UWF FAF imaging has been hindered by optical
distortions inherent to the UWF FAF platform as well as no
real-time averaging to reduce background noise.8 Ultrawideﬁeld FAF image analysis depends on high-quality,
well-centered images that can be affected by several artefacts, potentially inﬂuencing our results and area calculations for DDAF size. In addition, some of our patients had
difﬁculty ﬁxating on a central target, and consequently some
of the images obtained may have centration issues and may
have deviated from the standard retinal region typically
captured by Optos.

In summary, we demonstrated the feasibility and reliability of using UWF FAF to detect atrophy ER in STGD1.
Ultra-wideﬁeld FAF offers many advantages, including
better visualization of the perifoveal and equatorial retina,
ability to capture (duration, 250 ms) retinal lesions rapidly in
undilated children, and a more comfortable photography
experience (l, 532 nm, green ﬂash) for the patients. We
demonstrated genotype-dependent variations in ER and
found that patients belonging to genotype group C showed a
signiﬁcantly slower DDAF SRA ER. Further multicenter
studies of UWF FAF DDAF area expansion and its correlation with other pathogenic ABCA4 variants are warranted.
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